| CPC A61K 9/0034 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1647 (2013.01); A61K 9/1652 (2013.01); A61K 9/5153 (2013.01); A61K 38/1825 (2013.01); A61K 47/60 (2017.08); A61K 48/0041 (2013.01); A61P 7/00 (2018.01); A61P 11/00 (2018.01)] | 13 Claims |
|
1. A method comprising administering by injection into the amniotic fluid of a 15 to 20 week human embryo or fetus having exposed spinal cord or brain tissue, an effective amount of a composition comprising fibroblast growth factor encapsulated, entrapped, complexed to or dispersed in polymeric microparticles having a diameter from about 5 to about 10 microns and a zeta potential between −32.8 and −47 mV to cause epithelial tissue to form over the exposed spinal cord or brain tissue in the embryo or fetus, wherein the microparticles are formed of alginate, poly(lactic acid)(PLA), poly(glycolic acid)(PGA), poly(lactide-co-glycolide)(PLGA), polyanhydrides, poly(ortho) esters, poly(caprolactone), poly(hydroxyalkanoates), poly(lactide-co-caprolactone), poly(beta-amino) esters (PBAEs) or poly(amine-co-ester) polymers(PACE).
|